share_log

復星醫藥：聯合公告 - 寄發有關以吸收合併復宏漢霖之方式由復星新藥對復宏漢霖私有化之建議之綜合文件

FOSUN PHARMA: JOINT ANNOUNCEMENT - DESPATCH OF COMPOSITE DOCUMENT IN RELATION TO THE PROPOSED PRIVATISATION OF HENLIUS BY FOSUN NEW MEDICINE BY WAY OF MERGER BY ABSORPTION OF HENLIUS

HKEX ·  Dec 22 18:23

Summary by Moomoo AI

復星新藥、復星醫藥及復宏漢霖於2024年12月23日聯合公告，已就復星新藥以吸收合併方式對復宏漢霖進行私有化的建議寄發綜合文件。獨立董事委員會及獨立財務顧問建議獨立H股股東投票贊成合併，並選擇現金選擇。臨時股東大會及H股類別股東大會將於2025年1月22日舉行，以考慮批准合併協議及相關事項。本公司將於2025年1月17日至22日暫停辦理股份過戶登記。H股最後交易日預計為2025年2月4日，撤銷上市日期預計為2025年2月7日。股東須於2025年2月28日前遞交選擇表格以選擇現金選擇或股份選擇。現金選擇將於生效日期後7個營業日內結算，股份選擇將於生效日期後42個營業日內結算。合併仍須滿足多項條件方可實施，股東及投資者買賣本公司證券時務請審慎行事。
復星新藥、復星醫藥及復宏漢霖於2024年12月23日聯合公告，已就復星新藥以吸收合併方式對復宏漢霖進行私有化的建議寄發綜合文件。獨立董事委員會及獨立財務顧問建議獨立H股股東投票贊成合併，並選擇現金選擇。臨時股東大會及H股類別股東大會將於2025年1月22日舉行，以考慮批准合併協議及相關事項。本公司將於2025年1月17日至22日暫停辦理股份過戶登記。H股最後交易日預計為2025年2月4日，撤銷上市日期預計為2025年2月7日。股東須於2025年2月28日前遞交選擇表格以選擇現金選擇或股份選擇。現金選擇將於生效日期後7個營業日內結算，股份選擇將於生效日期後42個營業日內結算。合併仍須滿足多項條件方可實施，股東及投資者買賣本公司證券時務請審慎行事。
On December 23, 2024, FOSUN PHARMA, HENLIUS, and FOSUN Pharmaceuticals jointly announced that comprehensive documents regarding the proposal for FOSUN PHARMA to privatize HENLIUS through a merger have been sent out. The independent board committee and independent financial advisor recommend that independent H share shareholders vote in favor of the merger and choose the cash option.The extraordinary general meeting of shareholders and the H share class meeting will be held on January 22, 2025, to consider approving the merger agreement and related matters. The company will suspend share transfer registration from January 17 to January 22, 2025. The last trading day for H shares is expected to be February 4, 2025, and the delisting date is expected to be February 7, 2025.Shareholders must submit their selection forms by February...Show More
On December 23, 2024, FOSUN PHARMA, HENLIUS, and FOSUN Pharmaceuticals jointly announced that comprehensive documents regarding the proposal for FOSUN PHARMA to privatize HENLIUS through a merger have been sent out. The independent board committee and independent financial advisor recommend that independent H share shareholders vote in favor of the merger and choose the cash option.The extraordinary general meeting of shareholders and the H share class meeting will be held on January 22, 2025, to consider approving the merger agreement and related matters. The company will suspend share transfer registration from January 17 to January 22, 2025. The last trading day for H shares is expected to be February 4, 2025, and the delisting date is expected to be February 7, 2025.Shareholders must submit their selection forms by February 28, 2025, to choose either the cash option or the share option. The cash option will be settled within 7 business days after the effective date, while the share option will be settled within 42 business days after the effective date. The merger must still meet multiple conditions before it can be implemented, and shareholders and investors should exercise caution when trading the company's securities.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Related Stocks Related Stocks
    Symbol Mini Chart Latest Price
    NEP INTERLONG
    08329
    -- 0.160
    HIGHTIDE-B
    02511
    -- 1.140
    AIM VACCINE
    06660
    -- 6.380
    PURAPHARM
    01498
    -- 0.600
    UNI-BIO GROUP
    00690
    -- 0.062

    Unlock the Full List